​

Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PCRX Stock Forecast

Pacira BioSciences (PCRX) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $27.25, with a high of $48.00 and a low of $12.00. This represents a 10.55% increase from the last price of $24.65.

$10 $18 $26 $34 $42 $50 High: $48 Avg: $27.25 Low: $12 Last Closed Price: $24.65

PCRX Stock Rating

Pacira BioSciences stock's rating consensus is Buy, based on 33 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (45.45%), 14 Hold (42.42%), 4 Sell (12.12%), and 0 Strong Sell (0.00%).

Buy
Total 33 0 4 14 15 Strong Sell Sell Hold Buy Strong Buy

PCRX Price Target Upside V Benchmarks

TypeNameUpside
StockPacira BioSciences10.55%
SectorHealthcare Stocks 35.25%
IndustrySpecialty & Generic Drug Manufacturers Stocks47.55%

Price Target Trends

1M3M12M
# Anlaysts-39
Avg Price Target-$32.33$30.00
Last Closing Price$24.65$24.65$24.65
Upside/Downside-31.16%21.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25213-17
Mar, 25214-18
Feb, 25214-18
Jan, 25214119
Dec, 24214119
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025Barclays$24.00$24.05-0.21%-2.64%
Jan 30, 2025Les SulewskiTruist Financial$25.00$26.03-3.96%1.42%
Nov 07, 2024David AmsellemPiper Sandler$12.00$17.37-30.92%-51.32%
Sep 24, 2024Glen SantangeloJefferies$18.00$14.7721.87%-26.98%
Aug 13, 2024Les SulewskiTruist Financial$8.00$12.29-34.91%-67.55%
Jul 02, 2024Oren LivnatH.C. Wainwright$57.00$21.91160.16%131.24%
Jun 13, 2024Glen SantangeloJefferies$36.00$28.5026.32%46.04%
May 21, 2024David AmsellemPiper Sandler$42.00$30.6836.90%70.39%
Jan 06, 2023BMO Capital$52.00$38.5035.06%110.95%
Jan 06, 2023Needham$63.00$38.5063.64%155.58%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025RBC CapitalSector PerformSector Performhold
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 07, 2024Piper SandlerNeutralNeutralhold
Sep 24, 2024Truist FinancialSector PerformSector Performhold
Sep 24, 2024JefferiesBuyBuyhold
Aug 12, 2024RBC CapitalSector PerformSector Performhold
Aug 12, 2024RBC CapitalUnderperformSector Performdowngrade
Aug 12, 2024Raymond JamesUnderperformMarket Performdowngrade
Aug 12, 2024Piper SandlerBuyNeutraldowngrade
Jul 25, 2024Piper SandlerBuyBuyhold

Financial Forecast

EPS Forecast

$-3 $-1 $1 $3 $5 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.41$0.95$0.35$0.91$-2.15----
Avg Forecast$2.14$2.91$2.63$2.91$3.13$3.29$3.72$4.23$4.66
High Forecast$2.43$3.30$3.01$3.02$3.39$3.92$5.35$6.29$5.89
Low Forecast$1.66$2.26$1.91$2.78$3.00$2.73$2.02$1.76$3.34
Surprise %59.35%-67.35%-86.69%-68.73%-168.69%----

Revenue Forecast

$350M $490M $630M $770M $910M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$420.83M$541.53M$666.82M$674.98M$700.97M----
Avg Forecast$430.43M$536.73M$666.80M$674.23M$696.42M$715.50M$757.03M$776.28M$836.93M
High Forecast$474.19M$591.28M$740.69M$674.89M$777.84M$930.36M$757.05M$934.96M$1.01B
Low Forecast$355.94M$443.84M$526.79M$673.31M$674.92M$564.23M$757.01M$607.29M$654.74M
Surprise %-2.23%0.90%0.00%0.11%0.65%----

Net Income Forecast

$-100M $-10M $80M $170M $260M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$145.52M$41.98M$15.91M$41.95M$-99.56M----
Avg Forecast$135.29M$38.43M$46.47M$41.95M$165.98M$172.79M$191.65M$209.41M$241.96M
High Forecast$164.28M$48.01M$57.84M$52.23M$175.95M$203.60M$278.22M$327.18M$306.26M
Low Forecast$106.29M$28.85M$35.09M$31.68M$156.01M$141.97M$105.08M$91.63M$173.49M
Surprise %7.57%9.24%-65.76%--159.98%----

PCRX Forecast FAQ

Is Pacira BioSciences stock a buy?

Pacira BioSciences stock has a consensus rating of Buy, based on 33 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 14 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Pacira BioSciences is a favorable investment for most analysts.

What is Pacira BioSciences's price target?

Pacira BioSciences's price target, set by 33 Wall Street analysts, averages $27.25 over the next 12 months. The price target range spans from $12 at the low end to $48 at the high end, suggesting a potential 10.55% change from the previous closing price of $24.65.

How does Pacira BioSciences stock forecast compare to its benchmarks?

Pacira BioSciences's stock forecast shows a 10.55% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the specialty & generic drug manufacturers stocks industry (47.55%).

What is the breakdown of analyst ratings for Pacira BioSciences over the past three months?

  • April 2025: 28.57% Strong Buy, 14.29% Buy, 42.86% Hold, 0% Sell, 14.29% Strong Sell.
  • March 2025: 25.00% Strong Buy, 12.50% Buy, 50.00% Hold, 0% Sell, 12.50% Strong Sell.
  • February 2025: 25.00% Strong Buy, 12.50% Buy, 50.00% Hold, 0% Sell, 12.50% Strong Sell.

What is Pacira BioSciences’s EPS forecast?

Pacira BioSciences's average annual EPS forecast for its fiscal year ending in December 2025 is $3.29, marking a -253.02% decrease from the reported $-2.15 in 2024. Estimates for the following years are $3.72 in 2026, $4.23 in 2027, and $4.66 in 2028.

What is Pacira BioSciences’s revenue forecast?

Pacira BioSciences's average annual revenue forecast for its fiscal year ending in December 2025 is $715.5M, reflecting a 2.07% increase from the reported $700.97M in 2024. The forecast for 2026 is $757.03M, followed by $776.28M for 2027, and $836.93M for 2028.

What is Pacira BioSciences’s net income forecast?

Pacira BioSciences's net income forecast for the fiscal year ending in December 2025 stands at $172.79M, representing a -273.55% decrease from the reported $-99.56M in 2024. Projections indicate $191.65M in 2026, $209.41M in 2027, and $241.96M in 2028.